Literature DB >> 27730543

MicroRNA-133a suppresses the proliferation, migration, and invasion of laryngeal carcinoma cells by targeting CD47.

Hui Li1, Yan Wang2,3, Yan-Zhong Li4,5.   

Abstract

The study aims to investigate the possible mechanisms of microRNA-133a (miR-133a) targeting CD47 on cell proliferation, apoptosis, migration, and invasion in laryngeal carcinoma. Forty-two laryngeal carcinoma tissue specimens confirmed by pathological examination from laryngeal carcinoma patients as the case group were collected, and 20 chronic laryngitis tissues were gathered as the control group. The human laryngeal carcinoma cell line Hep-2 was marked as the miR-133a mimic, negative control (NC), miR-133a inhibitor, CD47-siRNA, miR-133a inhibitor + CD47-siRNA, and Mock groups. The expression of CD47 protein and miR-133a was detected by immunohistochemistry (IHC) and qRT-PCR. Dual luciferase assay system was used to determine the relationship between CD47 and miR-133a. Western blotting was used to measure the protein expression of CD47 and miR-133a. 5-Ethynyl-2'-deoxyuridine (EDU) method was used to detect the cell proliferation, and flow cytometry and Transwell were used to measure the cell apoptosis and migration and invasion, respectively. The miR-133a expression in laryngeal carcinoma tissues was significantly lower, while the CD47 expression was higher than that in chronic laryngitis tissues (both P < 0.01). The expression of miR-133a in the miR-133a mimic group was significantly higher than that in other groups (P < 0.05), and the messenger RNA (mRNA) and protein expression of CD47 in the CD47-siRNA and miR-133a mimic groups were significantly lower than those in the Mock and NC group (all P < 0.05), while the mRNA and protein expression of CD47 in the miR-133a inhibitor group were higher than in other groups (all P < 0.05). After transfection, the CD47-siRNA group had the strongest inhibitory activity, while the number of living cells in the miR-133a inhibitor group was significantly higher than that in other groups (all P < 0.05). The apoptosis rates in the miR-133a mimic and CD47-siRNA groups were significantly higher than that in the Mock and NC groups (all P < 0.05). The cell numbers that penetrated membrane in the miR-133a mimic and CD47-siRNA groups were less than in the Mock and NC groups (all P < 0.05). Upregulated miR-133a could inhibit proliferation, invasion, and migration and promote cell apoptosis in laryngeal carcinoma by targeting CD47. miR-133a targeting CD47 could be a new direction in the diagnosis and treatment of laryngeal carcinoma.

Entities:  

Keywords:  Apoptosis; CD47; Invasion; Laryngeal carcinoma; MicroRNA-133a; Migration; Proliferation

Year:  2016        PMID: 27730543     DOI: 10.1007/s13277-016-5451-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  38 in total

1.  [Primary, study of miRNA expression patterns in laryngeal carcinoma by microarray].

Authors:  Ping Wang; Tao Fu; Xurui Wang; Wei Zhu
Journal:  Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi       Date:  2010-06

2.  Staging of laryngeal carcinoma: comparison of high-frequency sonography and contrast-enhanced computed tomography.

Authors:  Q Hu; F Luo; S Y Zhu; Z Zhang; Y P Mao; X Hui Guan
Journal:  Clin Radiol       Date:  2011-09-28       Impact factor: 2.350

3.  MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin.

Authors:  Ka Bian; Jing Fan; Xiang Zhang; Xin-Wei Yang; Hua-Yu Zhu; Lei Wang; Jian-Yong Sun; Yan-Ling Meng; Peng-Cheng Cui; Shi-Yin Cheng; Jian Zhang; Jing Zhao; An-Gang Yang; Rui Zhang
Journal:  FEBS Lett       Date:  2012-02-01       Impact factor: 4.124

4.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

5.  CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.

Authors:  Siddhartha Jaiswal; Catriona H M Jamieson; Wendy W Pang; Christopher Y Park; Mark P Chao; Ravindra Majeti; David Traver; Nico van Rooijen; Irving L Weissman
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

6.  World Medical Association publishes the Revised Declaration of Helsinki.

Authors:  P Nischal M
Journal:  Natl Med J India       Date:  2014 Jan-Feb       Impact factor: 0.537

7.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.

Authors:  Stephen B Willingham; Jens-Peter Volkmer; Andrew J Gentles; Debashis Sahoo; Piero Dalerba; Siddhartha S Mitra; Jian Wang; Humberto Contreras-Trujillo; Robin Martin; Justin D Cohen; Patricia Lovelace; Ferenc A Scheeren; Mark P Chao; Kipp Weiskopf; Chad Tang; Anne Kathrin Volkmer; Tejaswitha J Naik; Theresa A Storm; Adriane R Mosley; Badreddin Edris; Seraina M Schmid; Chris K Sun; Mei-Sze Chua; Oihana Murillo; Pradeep Rajendran; Adriel C Cha; Robert K Chin; Dongkyoon Kim; Maddalena Adorno; Tal Raveh; Diane Tseng; Siddhartha Jaiswal; Per Øyvind Enger; Gary K Steinberg; Gordon Li; Samuel K So; Ravindra Majeti; Griffith R Harsh; Matt van de Rijn; Nelson N H Teng; John B Sunwoo; Ash A Alizadeh; Michael F Clarke; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

Review 8.  CD47 signaling pathways controlling cellular differentiation and responses to stress.

Authors:  David R Soto-Pantoja; Sukhbir Kaur; David D Roberts
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-02-24       Impact factor: 8.250

Review 9.  Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47.

Authors:  David R Soto-Pantoja; Erica V Stein; Natasha M Rogers; Maryam Sharifi-Sanjani; Jeffrey S Isenberg; David D Roberts
Journal:  Expert Opin Ther Targets       Date:  2012-10-27       Impact factor: 6.902

10.  The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer.

Authors:  H Yoshino; T Chiyomaru; H Enokida; K Kawakami; S Tatarano; K Nishiyama; N Nohata; N Seki; M Nakagawa
Journal:  Br J Cancer       Date:  2011-02-08       Impact factor: 7.640

View more
  8 in total

1.  CD47 (Cluster of Differentiation 47).

Authors:  Sukhbir Kaur; Jeffrey S Isenberg; David D Roberts
Journal:  Atlas Genet Cytogenet Oncol Haematol       Date:  2021

2.  CD47 is a direct target of SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT.

Authors:  Muhammad Zaeem Noman; Kris Van Moer; Vanessa Marani; Robert M Gemmill; Léon-Charles Tranchevent; Francisco Azuaje; Arnaud Muller; Salem Chouaib; Jean Paul Thiery; Guy Berchem; Bassam Janji
Journal:  Oncoimmunology       Date:  2018-02-15       Impact factor: 8.110

Review 3.  Checkpoint CD47 Function On Tumor Metastasis And Immune Therapy.

Authors:  Yusheng Lu; Lee Jia; Shu Lian; Xiaodong Xie
Journal:  Onco Targets Ther       Date:  2019-11-04       Impact factor: 4.147

4.  MicroRNA-133a inhibits the proliferation of non-small cell lung cancer by targeting YES1.

Authors:  Yuyao Shen; Fangwei Chen; Yanchao Liang
Journal:  Oncol Lett       Date:  2019-11-01       Impact factor: 2.967

Review 5.  Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?

Authors:  Chilam Chan; Marta Lustig; Niklas Baumann; Thomas Valerius; Geert van Tetering; Jeanette H W Leusen
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

6.  Third-Generation Anti-CD47-Specific CAR-T Cells Effectively Kill Cancer Cells and Reduce the Genes Expression in Lung Cancer Cell Metastasis.

Authors:  Huyen Thi La; Dao Bich Thi Tran; Hai Manh Tran; Linh Trong Nguyen
Journal:  J Immunol Res       Date:  2021-06-02       Impact factor: 4.818

Review 7.  Regulation of CD47 expression in cancer cells.

Authors:  Can-Yu Huang; Zi-Han Ye; Mu-Yang Huang; Jin-Jian Lu
Journal:  Transl Oncol       Date:  2020-09-10       Impact factor: 4.243

Review 8.  Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges.

Authors:  Muhammad Zaeem Noman; Meriem Hasmim; Audrey Lequeux; Malina Xiao; Caroline Duhem; Salem Chouaib; Guy Berchem; Bassam Janji
Journal:  Cells       Date:  2019-09-14       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.